Newest Harris Poll shows decrease in cigarette smoking but increase in obesity
ROCHESTER , N.Y. New findings from the Harris Poll have shown that through a 25-year period the amount of smokers has decreased, but the problem of obesity has risen. The Harris Poll was conducted by Harris interactive who is known as one of the largest market research firms, which through the poll, study the trends of the American public’s habits.
The poll, which is conducted every year, consisted of a nationwide telephone survey of 1,010 adults to ask about certain healthy or un-healthy behaviors, which include smoking, obesity and seat belt use.
According to published reports, only 17 percent of adults smoke cigarettes as opposed to the 30 percent that smoked in 1983. Through multi-year averages cigarette consumption has fallen to 21 percent from 2006 to 2008 as opposed to 29 percent in the 1980s.
In the weight category, the poll found that twenty-five years ago 58 percent of adults over 25 were overweight, and now the number has risen to 78 percent of adults. When questioning obesity in adults the survey found that 33 percent of adults were obese while in the 1980s the number was only 15 percent.
Possible new FDA diabetes drug guidelines could delay approvals
SAN DIEGO A draft of new guidelines proposed by the Food and Drug Administration for developing drugs to treat diabetes may lead to a delay of the approval for a new long-acting diabetes drug from Amylin Pharmaceuticals, according to the Associated Press.
The FDA suggested increased testing for macrovascular complications, or diseases affecting large veins, particularly for drugs that are linked to problems with those veins.
That could delay approval of Amylin’s diabetes drug candidate exenatide LAR, a weekly version of its Byetta treatment and a Type 2 injectable diabetes drug, which it co-manufactures with Eli Lilly, Lazard Capital Markets analyst Matthew Osborne wrote in a note to clients Monday. He said the guidelines could make clinical trials of diabetes drugs more expensive and difficult.
FDA approves Ranbaxy’s generic version of Risperdal
NEW DELHI, India Ranbaxy Laboratories has received approval from the Food and Drug Administration for a generic version of Janssen Pharmaceuticals’ schizophrenia drug, Risperdal, according to published reports.
Risperdal is also used to treat such behavior problems as aggression and self-injury, as well as sudden mood changes in teenagers and autism in children. The company has received approval to launch the generic risperidone in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths.
Risperdal had sales of $924 million in 2007.